Amicogen Succeeds in Attracting 10 Billion Won Investment… Largest Shareholder to Change to YK Bio Nova Holdings

Bio company Amicogen announced on the 22nd that it has decided on a third-party allotment paid-in capital increase worth about 10 billion won to secure operating funds and achieve management objectives.

The new shares to be issued through this paid-in capital increase are 8,554,319 common shares, and the issue price per share is 1,169 won, which applies a 10% discount rate to the base share price (1,298 won). The entire raised funds (approximately 9.99999 billion won) will be used as operating funds, such as for the company's business activities.

The target of the third-party allotment is 'YK Bio Nova Holdings Co., Ltd.' (CEO Lee Dong-jin). Amicogen stated, "It was selected by comprehensively considering the achievement of the company's management objectives, the investor's investment intention, payment ability, and timing." Once the payment for this paid-in capital increase is completed, the largest shareholder is scheduled to change to YK Bio Nova Holdings.

The entire attracted funds are planned to be injected into operating funds, such as the company's business activities, within this year and utilized to strengthen corporate competitiveness.

The payment date for the shares is July 15, and the scheduled listing date for the new shares is August 10. Meanwhile, to protect investors and control the circulation volume, the entire volume of new shares issued through this paid-in capital increase will be deposited with the Korea Securities Depository immediately upon issuance and registered for mandatory holding (lock-up) for one year.